CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.

Breast cancer rises as the most commonly diagnosed cancer in 2020. Among women, breast cancer ranks first in both cancer incidence rate and mortality. Treatment resistance developed from the current clinical therapies limits the efficacy of therapeutic outcomes, thus new treatment approaches are urgently needed. Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy developed from adoptive T cell transfer, which typically uses patients' own immune cells to combat cancer. CAR-T cells are armed with specific antibodies to recognize antigens in self-tumor cells thus eliciting cytotoxic effects. In recent years, CAR-T cell therapy has achieved remarkable successes in treating hematologic malignancies; however, the therapeutic effects in solid tumors are not up to expectations including breast cancer. This review aims to discuss the development of CAR-T cell therapy in breast cancer from preclinical studies to ongoing clinical trials. Specifically, we summarize tumor-associated antigens in breast cancer, ongoing clinical trials, obstacles interfering with the therapeutic effects of CAR-T cell therapy, and discuss potential strategies to improve treatment efficacy. Overall, we hope our review provides a landscape view of recent progress for CAR-T cell therapy in breast cancer and ignites interest for further research directions. © The author(s).

Background

The global cancer statistics in 2020 shows breast cancer has overridden lung cancer and become the most commonly diagnosed cancer worldwide, with 2.3 million new cases in 11.7% of all cancer types reported1. Moreover, breast cancer mortality ranks the 5th, with 685,000 patient deaths in 20201. Among women, breast cancer was diagnosed 1 in 4 cancer cases and 1 in 6 cancer death were caused by breast cancer, ranking the first in both incidence rate and cancer mortality1. The histological classification of breast cancer is mainly based on the expression pattern of human epidermal growth factor receptors 2 (HER2) and hormone receptors (HR) named as estrogen receptors (ER) and progesterone receptors (PR), as well as the tumor proliferation rate indicated by Ki-67, resulting in classified 5 major subtypes: HER2 positive, HR positive (HER2+ and ER+ or PR+ or both positive); HER2 positive, HR negative (HER2+/ER-/PR-); basal-like or triple negative (HER2-/ER-/PR-); luminal A (HER2-/ER+/PR+, low proliferation); and luminal B (HER2-/ER+/PR+, high proliferation)2. The breast cancer treatment is systemic or local, based on the breast cancer subtype and metastasis degree. For nonmetastatic breast cancer, the main therapeutic goals are eradicating tumors from patients and preventing tumor recurrence. Local therapies including surgery and radiation are used for tumor eradication, while systemic therapies consisting of endocrine therapy, chemotherapy, and immunotherapy are used for further eradication and recurrence prevention. Systemic therapy may be neoadjuvant (preoperative), adjuvant (postoperative), or both. Breast cancer subtypes guide the treatment approaches, such as chemotherapy alone for triple-negative breast cancer, endocrine therapy for all HER2-/ER+/PR+ tumor, and immunotherapy (trastuzumab-based HER2-directed antibody) for all HER2+ tumor. For metastatic breast cancer, local therapy approaches along with systemic therapy approaches are typically used to reach the main therapy goals of symptom alleviation and prolonging life3.In recent decades, surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy have improved the survival rate and life quality of breast cancer patients4, 5. However, the mortality of breast cancer remains high largely due to the fact the developed resistance in patients therapy limits the therapeutic efficacy and treatment outcome6-8. Therefore, new treatment strategies are urgently needed to further improve breast cancer survival and life quality of patients.

Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy developed from adoptive T cell transfer (ACT)9. In this procedure, patient's T cells are isolated from autologous peripheral blood and further engineered ex vivo to express synthetic receptors that recognize tumor-associated antigens (TAAs). Afterwards, CAR-T cells are cultured ex vivo for amplification and then infused back to patients as an anti-cancer treatment10. Typically, CARs are composed of four segments (Figure 1 A), including an extracellular domain usually containing a single-chain variable fragment (scFv) derived from the variable region of antibodies for tumor antigen recognition, an extracellular spacer regulating the distance between CAR-T cells and tumor cells, a transmembrane domain gluing the synthetic CARs to patient's T cell membrane, and an intracellular signaling domain which consists CD3ζ and costimulatory domains for T cell activation9-14. When contacting tumor cells, CAR-T cells specifically recognize antigens presenting on the surface of tumor cells (Figure 1B). The clinical results of the first generation of CAR-T cell therapy are unsatisfying because the CAR-T cells show poor persistence and fail for expansion15-17. To solve these issues, CARs are further engineered with costimulatory signaling domains (Figure 1C). Compared with the first generation of CARs, the second generation adds one costimulatory domain (e.g., CD28, 41BB, ICOS) to the CARs to improve the retention period18. The third generation of CARs further include two extra costimulatory domains (e.g., CD27, CD28, 41BB, ICOS, and OX-40) to enhance the persistence and the cytocidal capacity of T cells19, 20. The fourth generation of CARs, also known as T cells redirected for universal cytokine-mediated killing [TRUCKs], adds a nuclear factor of activated T cells (NFAT) domain harboring an inducible IL-12 cassette21, 22. In this generation, pro-inflammatory cytokine IL-12 is released and accumulated in the targeted region after CAR-T cells recognize tumor antigens and activate the downstream signaling pathways. Subsequently, the innate immune cells, including NK cells and macrophages, are recruited to tumors to modulate the tumor microenvironment and destroy the cancer cells22, 23. The fifth generation of CARs is currently under evaluations for safety and efficacy, and it is derived from the second generation of CARs with an extra IL-2 receptor β-chain fragment (IL-2Rβ). The IL-2Rβ fragment bears a binding site to trigger JAK-STAT signaling pathway activation. Once the CAR-T cells target tumor antigens, the antigen-specific activation of the receptor can trigger all the downstream signaling pathways at once, which results in T cells' full activation and persistence enhancement 14, 24, 25.

Figure 1

The introduction of CAR-T cells. (A) The structure of CARs containing four parts, an extracellular domain containing a single-chain variable fragment (scFv) for antigen recognition, a spacer, a transmembrane domain, and an intracellular signaling domain for T cell activation. (B) CAR-T cell recognizes tumor cells by binding to antigens that present on the surface of tumor cells. (C) The evolution of CAR-T cells. The first generation of CAR-T cells contains one signaling domain (CD3ζ), while two signaling domains (CD3ζ plus CD28/41BB/ICOS) for the second generation. The latter generations contain three intracellular signaling domains. The third generation owns CD3ζ, CD28/ICOS, and 41BB/CD27/OX-40. The fourth and fifth-generation each have a special domain named NFAT and IL-2Rβ plus the normal two signaling domains (CD3ζ and CD28/41BB/ICOS).

In 2017, two CAR-T cell therapies targeting CD19 named tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma) were approved by FDA for treating children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphomas (NHLs), respectively26-28. More recently, another CAR-T cell therapy named as brexucabtagene autoleucel (Tecartus, Kite Pharma) was approved for adult patients with relapsed or refractory mantle cell lymphoma (MCL) in 2020, followed by the approval of Lisocabtagene maraleucel (Breyanzi, BMC) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treatment in 202129, 30. The successful application of CAR-T cell therapy in hematologic cancers implies that CAR-T cell therapy might be a potential strategy for solid tumors as well. However, unlike hematologic cancers, solid tumors present several barriers to interfere with the activities of CAR-T cells, such as tumor heterogeneity, unfavorable tumor microenvironment, insufficient trafficking and infiltration, and toxicities11, 31-33. Therefore, in recent years, many efforts have been devoted to identifying unique antigens presenting in solid tumor cells and modifying CARs to fit better to solid tumors. Excitingly, several tumor antigens show encouraging results in preclinical studies, including members of receptor tyrosine kinase (RTK)34, 35, cell surface proteins36, ganglioside37, stress ligand38, tumor serum marker39 and others.

In this review, we focus on CAR-T cell therapy in breast cancers. We first summarize tumor antigens in breast cancer and their clinical relevance, followed by the development of antigen-specific CAR-T cells and their applications from basic research to clinical trials. In addition, we also discuss the challenges of CAR-T cell therapy in solid tumors, the efforts developed to overcome these changelings, and the strengths and weaknesses of those approaches. We hope our review will provide a timely update on CAR-T cell therapy in breast cancer and insights to further improve therapeutic efficacy.

Potential targets for CAR-T cell therapy in breast cancer

Tumor antigens are divided into three classifications based on the expression pattern, namely tumor-specific antigens (TSAs), tumor-associated antigens (TAAs), and cancer germline antigens (CGAs)40. TSAs are the most ideal tumor antigens expressing only on tumor cell surface, including tumor-specific glycosylation (e.g., TnMUC1)41. TAAs are more enriched on tumor cells compared with normal tissues (e.g., human epidermal growth factor receptor 2, HER2)34, or linear-restrict expression on normal cells (e.g., CD 19)42. Targeting TAAs harbors a potential risk for on-target/off-tumor side effects as normal tissues are also attacked by armed CAR-T cells43, 44. The expression of CGAs is restricted to adult somatic tissues as they are mainly expressed in testis and ovaries45. The potential tumor antigens that can be targeted for CAR-T cell therapy in breast cancer are summarized in Table 1. Most of these antigen targets belong to the RTK family and cell surface proteins, while others are stress ligands, disialoganglioside, and serum tumor markers. The downstream signaling pathways of these targets in tumors are summarized in Figure 2. The majority of CAR-T cell targets of breast cancer are TAAs. We will discuss in detail in the following sections for these breast cancer antigens.

Table 1

CAR-T cell targets in breast cancer.

CAR-T cell target	Class of target	Relationship with breast cancer
HER2/ERBB2	Receptor tyrosine kinase (RTK)	Nearly 20%-30% of patients are observed with HER2 gene amplification or HER2 overexpression, correlated with poor clinical outcomes, poor prognosis, and disease progression51-53.
EGFR/ERBB1	Receptor tyrosine kinase (RTK)	15-30% of breast cancer patients are associated with EGFR overexpression with poor clinical outcomes and larger tumor sizes at diagnosis60, 61.
HGFR/cMET	Receptor tyrosine kinase (RTK)	Overexpression of cMET and HGF accounts for 20-30% of breast cancers and is associated with poor prognosis68, 69.
ROR1	Receptor tyrosine kinase (RTK)	In breast cancer, increased ROR1 expression induces expression of ATP-dependent drug efflux pumps (ABCB1), resulting in chemotherapy resistance and tumor recurrence75.
AXL	Receptor tyrosine kinase (RTK)	Overexpressed AXL is a strong predictor of poor survival and clinical outcomes82.
MUC1	Cell surface glycoprotein	MUC1 overexpression was found in almost 90% of breast cancers88.
MSLN	Cell surface glycoprotein	Breast cancer patients with MSLN overexpression are correlated with poor clinical outcomes and a greater risk of developing chemo-resistance98-100.
CD70	Cell surface glycoprotein	The role of CD70 in breast cancer has been controversial110.
CD133	Cell surface glycoprotein	CD133 expression is elevated and correlated with poor prognosis and cancer progression in breast cancer patients112, 116.
CD44v6	Cell surface glycoprotein	Upregulation of CD44v6 has been detected in breast cancers, especially in invasive breast cancer cell lines123.
EpCAM	Cell surface glycoprotein	Highly expressed EpCAM contributes to tumor growth, metastasis, and therapy resistance, leading to shorter disease-free and overall survival in breast cancer patients126, 127.
CSGP4	Cell surface glycoprotein	Overexpression of CSGP4 plays an essential role in cancer progression and chemoresistance, resulting in poorer overall survival (OS) and shortened recurrence (TTR)135.
ICAM1	Cell surface glycoprotein	Overexpression of ICAM1 has been reported in various cancer, including breast cancer140, 141.
TEM8	Cell surface glycoprotein	The elevated expression of TEM8 was associated with a higher risk of tumor relapse143.
TROP2	Cell surface glycoprotein	Overexpression of TROP2 correlates with poor clinical outcomes such as disease progression and short overall survival145.
FRα	Cell surface glycoprotein	In breast cancer, overexpression of FRα correlates with poor clinical outcomes such as shorter OS and TTR148.
GD2	Disialoganglioside	GD2 is a tumor antigen as its expression is highly specific to tumor cells37.
NGK2D Ligand	Stress ligand	In breast cancer patient samples, evaluation of NKG2D ligand expression showed that it was only expressed on the tumor cells162.
CEA	Serum tumor marker	CEA is one of the most commonly used serum tumor markers in metastatic breast cancer, which normally implies poor overall survival, disease-free survival, and a higher tumor burden39, 167.

Figure 2

Targets of CAR-T cell therapy in breast cancer and the downstream signaling pathways involved in cell activity regulation. The receptors present on the surface of tumor cells, NK cells, lymphocytes, and blood vessel cells. After ligand binding, they activate the downstream signaling pathways to regulate the cell activities. The downstream signaling pathways mainly fall into three cascades, namely PI3K/AKT, PLCγ/PKC, and JAK/STAT. Each cascade contains different downstream molecules. PI3K/AKT pathway and PLCγ/PKC pathway are involved in cell survival, proliferation, migration, and apoptosis. JAK/STAT pathway regulates cell migration and tumor angiogenesis. Down the signaling pathways, the signal is transduced to the nucleus and generates the corresponding proteins (such as anti-apoptotic protein: Bcl-xl, Bcl-2) and activities (such as angiogenesis, cell proliferation, differentiation, migration).

Receptor tyrosine kinase (RTK)

Receptor tyrosine kinases (RTKs) modulate the crucial cell activities such as proliferation, differentiation, metabolism, and survival after activation by growth factors or hormones35. Activation of RTKs triggers activation of downstream signaling pathways, including PI3K/AKT, Ras/MEK/ERK, PLCγ/PKC, and JAK/STAT, which plays an essential role in tumor development34. PI3K/AKT signaling pathway regulates cell survival, proliferation, migration, and apoptosis. Ras/MEK/ERK and PLCγ/PKC pathways are involved in cell proliferation, migration, and survival, while JAK/STAT pathway modulates angiogenesis and metastasis. In breast cancer, aberrant expression or hyperactivation of several RTKs have been reported including HER2, EGFR34. In this section, we focus on five RTKs as CAR-T cell therapy targets.

Human epidermal growth factor receptor 2 (HER2)

Human epidermal growth factor receptor 2 (HER2), also known as ERBB2, belongs to the HER/ERBB family of the receptor tyrosine-protein kinase (RTK) family46. Once activated, it triggers various downstream signaling pathways to promote expression of genes that encode epithelial-mesenchymal transition (EMT), resulting in the initiation of tumor metastasis47-49. HER2 dysfunction plays an essential role in the pathogenesis of several tumor types50. In breast cancer, nearly 20%-30% of patients are observed with HER2 gene amplification or HER2 overexpression, correlated with poor clinical outcomes, poor prognosis, and disease progression51-53. Besides, somatic mutations in HER2 gene also contribute to breast cancer development through activating HER2 signaling54. Therefore, HER2 is a potential target for breast cancer treatments.

The monoclonal antibodies targeting HER2, especially trastuzumab, the first targeted therapy approved by FDA for breast cancer, improved the clinical outcome of breast cancer patients in recent years55. In preclinical studies, HER2-CAR-T cells targeting HER2+ cancers demonstrated significant tumor growth inhibition56 and regression of brain tumor metastasis57. In addition, in trastuzumab-resistant JIMT-1 cell line derived xenograft mouse models, HER2-CAR-T cells penetrated into the tumor matrix and eradicated the established solid tumor, which subsequently resulted in an improved long-term survival58. Besides, even a smaller amount of HER2-targeted CAR-T cells evoked a robust immune reaction and ultimately resulted in tumor remission59. Collectively, these results suggest HER2 as a potential target for CAR-T cell therapy in breast cancer.

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) is also known as ERBB1 or HER1, belonging to the ERBB family. Once activated by ligand binding, it triggers the same downstream signaling pathways as HER234. Approximately 15-30% of breast cancer patients are associated with EGFR overexpression with poor clinical outcomes and larger tumor sizes at diagnosis60, 61. Notably, EGFR overexpression was mainly observed in triple-negative breast cancer (TNBC), a subtype of breast cancer with estrogen receptor-negative, progestogen receptor-negative, and HER2 negative, accounting for 45-70% of all TNBC patients62. Therefore, several EGFR targeted therapies are considered for TNBC treatment, including CAR-T therapy63, 64. The third-generation of CAR-T cells with an scFv region of anti-EGFR antibodies showed antitumor and cytotoxic effects in TNBC cell cultures (HS578T, MDA-MB-231, MDA-MB-468) and TNBC cell lines derived xenograft mouse models through mechanisms of enhancing cytokine release and tumor lysis62.

Hepatocyte growth factor receptor (HGFR)

Hepatocyte growth factor receptor (HGFR), also named cMET, belongs to the RTK family and is encoded by a proto-oncogene MET34. Once binding to hepatocyte growth factor (HGF), it activates the downstream signaling pathways to regulate tumor progression by controlling the differentiation, proliferation, migration, and apoptosis of tumor cells65-67. Overexpression of cMET and HGF accounts for 20-30% of breast cancers and is associated with poor prognosis68, 69. Besides, a study using small-interring RNA to silence the cMET in human TNBC cell lines showed an obvious reduction in tumor cell proliferation and migration67. Therefore, targeting cMET might be a potential strategy for breast cancer treatments. Indeed, the TNBC patients receiving cMET-CAR-T cells constructed by mRNA electroporation were well tolerated and the inflammatory response was evoked in tumor sites70. More recently, the dual function CAR-T cells targeting cMET and PD-1 at the same tumor cell enhanced the anti-tumor activities and T cell persistence71.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1)

Receptor tyrosine kinase-like orphan receptor 1(ROR1) also belongs to the RTK family. Highest expression of ROR1 is observed in embryogenesis with reduced expression during fetal development, and eventually disappears in terminally differentiated tissues72. Notably, high expression levels of ROR1 is also observed in a few malignancy cancers, including breast cancer73, 74. In breast cancer, increased ROR1 expression induces expression of ATP-dependent drug efflux pumps (ABCB1), resulting in chemotherapy resistance and tumor recurrence75. Notably, chemoresistance could be reversed by using either ROR1 specific antibodies or efflux pump inhibitors75, 76. Recently, the application of ROR1-CAR-T cells in a 3D microphysiologic tumor models of TNBC presented cytolytic activity and cytokine secretion that favor tumor killing77.

AXL

AXL is a member of the TAM family of RTKs78. Rather than functioning as a driver to initiate cancer transformation, AXL predominantly provides survival, metastatic signals and causes chemo-resistance79. Once activated, AXL autophosphorylation stimulates the downstream signaling pathways such as PI3K/AKT, MAPK, and JAK/STAT, therefore, controlling the cancer cell activities80. Among all breast cancers, AXL is especially highly expressed in TNBCs hence regarded as a marker of TNBC81. Overexpressed AXL is a strong predictor of poor survival and clinical outcomes82. The ATP-competitive inhibitors of AXL were reported to limit tumor progression by inhibiting cell activities and inducing apoptosis of breast cancer cells in animal models83. Collectively, targeting AXL is a potential strategy for breast cancer treatment. The co-culture of AXL-CAR-T cells and AXL-positive breast cancer cells (such as MDA-MB-231) in vitro resulted in increased cytokine release and direct cancer cell lysis compared with AXL-negative cancer cells (such as MCF-7). The same results were observed in MDA-MB-231 derived xenograft mouse models as tumor growth was inhibited by CAR-T therapy84. Moreover, the third generation of AXL-CAR-T cells demonstrated anti-tumor effects by inducing cytokine production and cell killing response in AXL-positive cancer cells in vitro85. In addition, a recent combination strategy of AXL-CAR-T plus constitutive active IL-7 receptor blockade exhibited strong cytotoxic effects in vitro and reduced tumor size in MDA-MB-231-derived xenograft mouse models86.

Cell surface proteins

Cell surface proteins are presented on the surface of tumor cells, which acts as tumor antigens for CAR-T cell recognition and aids the antitumor effects of T cells. There are 11 surface proteins with aberrantly increased expression in breast cancer that might be suitable for CAR-T cell therapy.

Mucin 1 (MUC1)

Mucin 1 (MUC1), a transmembrane glycoprotein, is usually expressed on the apical side of epithelial cells, secreting mucus to create a chemical barrier to protect host cells from pathogen infection87. In the extracellular domain of MUC1, a variable number of tandem repeats (VNTR) region is enriched with serine and proline residues which serves as attachment sites for O-glycans and allows the extensive O-linked glycosylation to take place88. The unique enormous O-glycosylation distinguish between tumor and normal cells, rendering MUC1 as an ideal candidate for immunotherapy target89. MUC1 overexpression was found in almost 90% of breast cancers88. The overexpressed MUC1 regulates tumor migration and progression by decreasing the adhesion capability90 and activating the downstream signaling pathways such as ERK1/2 and NFκB91. Clinically, breast cancer patients with MUC1 overexpression are associated with poor prognosis and advanced tumor stage92.

In TNBC preclinical studies, the second generation of tMUC1-CAR-T cells significantly increased the release of cytokines and chemokines in vitro and inhibited tumor growth in 9 TNBC cell lines derived xenograft mouse models88. Tn-MUC1 is another form of aberrantly glycated MUC1 expressed in breast cancer93. The preclinical studies about TnMUC1-CAR-T cell therapy were less reported, however, a phase I clinical trial of TnMUC1-CAR-T cell therapy was recruiting for TNBC (NCT04025216).

Mesothelin (MSLN)

Mesothelin (MSLN) is a cell surface protein and is normally expressed on the surface of mesothelial cells in a few tissues94. The biological effects of MSLN remain unclear given that deficiency in MSLN gene does not interfere with the development, reproduction, and growth in mouse models95. However, overexpression of MSLN has been observed in various solid tumors, including breast cancer96, especially in more aggressive and advanced subtypes97. Breast cancer patients with MSLN overexpression are correlated with poor clinical outcomes and a greater risk of developing chemo-resistance98-100. Overexpression of MSLN constitutively activates the intracellular signaling pathways (such as MAPK, PI3K, and NF-kB) to promote tumor development and progression99, 101. Therefore, targeting MSLN might be a potential strategy for cancer immunotherapies.

The CAR-T cells targeting MSLN in breast cancers mainly focus on TNBC. The third generation of MSLN-CAR-T cells triggered immune responses by releasing cytokines, exhibiting potent cytotoxicity in both MCF-7-Luc and MDA-MB-231-Luc breast cancer cells in vitro. Moreover, MSLN-CAR-T cell therapy inhibited tumor growth and metastasis in MDA-MB-231 xenograft models102. Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on the T cell surface, facilitating the cancer cells to escape immune surveillance. The combination of MSLN-CAR-T with programmed cell death protein 1 (PD-1) blockade strongly augmented the cytotoxicity and persistence of T cells within tumors103, 104. Furthermore, the fourth generation of anti-MSLN-CAR-T cells illustrated a dramatic antitumor capability with complete tumor regression and overall improved survival in mouse models105.

CD70

CD70 is a costimulatory factor encoded by tumor necrosis factor ligand superfamily member 7 (TNFLS7) and presented on the surface of activated T cells, B cells, and dendritic cells106. Normally, CD70 is only expressed in lymphoid tissues107, while CD70 overexpression has been found in several solid tumors108. Upon binding CD27, CD70 is activated to regulate cell proliferation, survival, and lymphocyte differentiation109. The role of CD70 in breast cancer has been controversial110. Several immune treatment strategies (such as monoclonal antibodies and CAR-T cells) targeting aberrantly expressed CD70 showed promising results in preclinical and clinical studies. Both humanized anti-CD70 antibodies and anti-CD70 antibody-drug conjugates exhibited remarkable antitumor effects in preclinical researches109. In addition, TanCAR-T cells targeting both CD70 and B7-H3 demonstrated enhanced tumor inhibition activities by inducing cytokine release and cytolysis111.

CD133

CD133, also named prominin 1, is a pentaspan transmembrane glycoprotein normally expressed on the protrusions of the plasma membrane112. CD133 has been observed to be enriched in cancer stem cells (CSCs). CSCs are a group of cancer cells sharing stem cell-like features that maintains self-renewal, infinitive differentiation, and proliferation, resulting in high tumorigenicity and treatment resistance113, 114. CD133 is a biomarker on the surface of CSCs and is regarded as the most rigorous predictor of malignant precursors in various solid tumors, including breast cancer115. Besides, CD133 expression is elevated and correlated with poor prognosis and cancer progression in breast cancer patients112, 116. Collectively, these features suggest CD133 as a potential target for immunotherapy117. In fact, CD133-targeted therapies exhibited excellent tumor suppression capacity in several solid tumors. In MDA-MB-231 xenograft models, delivering anti-CD133 antibodies and paclitaxel together significantly improved the therapeutic effects by suppressing the tumor growth and recurrence compared with the paclitaxel only group118. However, CD133-CAR-T cells specifically targeting breast cancer studies were less reported. Therefore, more investigations are needed to support the further application of CD133-CAR-T cell therapy in breast cancer.

CD44 containing variant exon v6 (CD44v6)

CD44 containing variant exon v6 (CD44v6) is the major variant of CD44, which is a cell surface glycoprotein involved in proliferation, motility, and survival119. CD44v6 plays a vital role in tumor development as it activates PI3K/Akt and MAPK signaling pathways to control cell apoptosis, invasion, and metastasis120-122. Upregulation of CD44v6 has been detected in breast cancers, especially in invasive breast cancer cell lines123. Downregulating CD44v6 by microRNA significantly suppressed the invasion and migration of tumor cells123. In addition, a meta-analysis showed that the overexpression of CD44v6 was correlated with poor overall survival, breast cancer lymph node metastasis, and more advanced histological stages124. These observations suggest CD44v6 as a potential target for breast cancer therapy. Although the preclinical results about CD44v6-CAR-T cell therapy in breast cancer is not well-understood, the clinical trials of anti-CD44v6 CAR-T cells against solid tumors are underway (NCT04427449).

Epithelial cell adhesion molecule (EpCAM)

Epithelial cell adhesion molecule (EpCAM) is a glycosylated cell surface protein overexpressed in various epithelial carcinomas, including breast cancer125. Highly expressed EpCAM contributes to tumor growth, metastasis, and therapy resistance, leading to shorter disease-free and overall survival in breast cancer patients126, 127. Therefore, blocking EpCAM on the surface of breast cancer cells can be an approach to inhibit tumor growth, metastasis and improve the therapeutic effects.

Indeed, extensive studies demonstrated the great effects of EpCAM targeted strategies in solid tumor treatments. The antibody-derived EpCAM-targeted methods manifested antitumor effects. For example, adecatumumab targeting EpCAM inhibited breast cancer metastasis in a dose and target-dependent manner, thus catumaxomab targeting EpCAM has already been approved for the treatment of cancers128. A cytolytic fusion protein targeting EpCAM illustrated a remarkable tumor inhibiting ability in a human TNBC cell-derived xenograft mouse model129. Furthermore, as compared with normal T cells, EpCAM-CAR-T cells induced more cytokine release (such as interferon‑γ, IL‑2, and IL‑6) and exhibited stronger apoptotic effects in cancer cells130. Meanwhile, the third generation of EpCAM-CAR-T cells elicited cytotoxic effects in an EpCAM-dependent manner and enormously inhibited tumor formation and growth by secreted high dose of cytokines such as INF-γ and TNF-α in MDA-MB-231 models both in vitro and in vivo131. Taken together, EpCAM as a cancer cell surface antigen displays an important role in targeted therapies.

Chondroitin sulfate proteoglycan 4 (CSPG4)

Chondroitin sulfate proteoglycan 4 (CSPG4) is a transmembrane protein overexpressed in several tumors, including breast cancer132. Within breast cancer, CSGP4 is highly expressed in more aggressive subtypes, especially basal-like breast cancer and TNBCs133, 134. Overexpression of CSGP4 plays an essential role in cancer progression and chemoresistance, resulting in poorer overall survival (OS) and shortened recurrence (TTR)135. These features make CSGP4 a clinically relevant target for tumor immunotherapy. The anti-CSGP4 monoclonal antibody co-culturing with TNBCs cells inhibited cell migration and growth, and also limited the tumor growth and metastasis in human TNBC cell-derived xenografts in immunodeficient mice by blocking the signaling pathways involved in cell proliferation, migration as well as survival133. Furthermore, the second generation of CAR-T cells targeting CSPG4 exhibited cytotoxic effects and induced cytokines production in vitro136. The CSGP4-CAR-T cells not only inhibited tumor progression by blocking the downstream signaling pathways but also regulated the TME to enhance T cell activities137. Together these data suggest that targeting CSGP4 shows an antitumor capability in breast cancer immunotherapies.

Intercellular adhesion molecule-1 (ICAM1)

Intercellular adhesion molecule-1 (ICAM1) is a surface glycoprotein that belongs to the immunoglobin superfamily. As a molecular adhesion receptor, ICAM1 plays a role in regulating cell activities including signaling transduction, cell adhesion, and migration138, 139. Overexpression of ICAM1 has been reported in various cancer, including breast cancer140, 141. Evidence suggested that increased ICAM1 mRNA and proteins were observed in TNBCs compared with other breast cancer subtypes and normal breast tissues. Blocking ICAM1 by antibodies in highly metastatic MDA-MB-435 cells exhibited a remarkable suppression of cell invasion and migration141. Therefore, ICAM1 seems to be a target for therapy. In fact, the coincubation of ICAM1-CAR-T cells with TNBC cells presented the specific and robust killing of cancer cells. While in in vivo studies using TNBC cell-derived mouse models, ICAM1-CAR-T cells significantly inhibited tumor growth and resulted in prolonged overall survival and long-term remission138.

Tumor endothelial marker 8 (TEM8)

Tumor endothelial marker 8 (TEM8), also known as an anthrax toxin receptor 1(ANTXR1), is a group of cell surface glycoproteins. It was identified in terms of its overexpression on epithelial cells of the tumor vasculature and its role in tumor angiogenesis142. In breast cancer, elevated expression of TEM8 was associated with a higher risk of tumor relapse143. Administration of antibodies blocking TEM8, or genetically knocking out TEM8 impaired tumor growth and metastasis142. The second and third generation of TEM8-specific CAR-T cells targeting TEM8 on TNBC cell lines including MDA-MB-231, MDA-MB-436, MDA-MB-468 and HS578T and human breast tumor endothelial cell line HC6020 demonstrated cytotoxic effects in vitro and inhibition of tumor initiation in MDA-MB-468 xenografts143. Although targeting TEM8 is a potential strategy to combat breast cancer, further investigations of TEM8-CAR-T cell studies are needed to explore TEM8-specific CARs before clinical studies.

Trophoblast cell surface protein 2 (TROP2)

Trophoblast cell surface protein 2 (TROP2) overexpression has been detected in breast cancers, especially TNBCs (approximately 90%)132, 144. TROP2 is an oncogene that drives cancer cell proliferation, migration, invasion, and metastasis. Overexpression of TROP2 correlates with poor clinical outcomes such as disease progression and short overall survival145. Therefore, targeting TROP2 might be a potential approach against TROP2-positive tumors. Indeed, FDA has approved an antibody-drug conjugate called sacituzumab govitecan targeting TROP2 for treating relapsed or refractory metastatic TNBC recently132. Human antibody targeting TROP2 elicited antitumor effects both in vitro and in vivo by inhibiting signaling molecules involved in cell survival146. In addition, the TROP2-CAR-T cells based on the CD27 intracellular domain showed stronger antitumor effects than a simple TROP2-CAR-T145. Collectively, although targeting TROP2 presents with tumor growth inhibition, the combination with other molecules might provide better clinical outcomes in CAR-T cell therapy.

Folate receptor alpha (FRα)

Folate receptor alpha (FRα) is a cell surface protein involved in the biosynthesis of nucleotide bases, amino acids, and methylated compounds, playing an important role in cancer development147. In breast cancer, overexpression of FRα correlates with poor clinical outcomes such as shorter OS and TTR148. Increased expression of FRα on tumor cells renders FRα an attractive target for therapies. In fact, FRα-CAR-T cells effectively targeted FRα-positive TNBC cells and elicited antitumor effects in MDA-MB-231 tumor xenograft, resulting in decreased tumor growth149. To improve safety, a trans-signaling CAR strategy was employed150. Two different signaling domains (CD3ζ and CD28) were constructed in two separate CARs and in one T cell to target two different antigens (mesothelin and FRα) in one tumor cell (Figure 3). Only when two CARs recognized antigen simultaneously, T cells were activated and elicited antitumor activities. Moreover, a folate-FITC (the conjugation of folate and fluorescein isothiocyanate) acted as a small molecular switch that redirected FITC-CAR-T cells towards FR overexpressing tumor cells also exhibiting cytotoxicity effects151.

Figure 3

A trans-signaling CAR-T cell strategy. A trans-signaling CAR-T cell strategy means T cell activation requires dual recognition and binding between CAR-T cells and antigens. Single recognition of each antigen is not able to activate the CAR-T cell.

Disialoganglioside (GD2)

Disialoganglioside (GD2) is a b-series acidic glycosphingolipid containing two sialic acid residues and facilitates the interaction between tumor cells and extracellular matrix proteins37, 132. GD2 is a tumor antigen as its expression is highly specific to tumor cells37. A small number of cancer cells with GD2 overexpression were able to form mammospheres and initiate tumor formation in mice. However, knockdown of GD3S, an essential enzyme involved in GD2 biosynthesis, completely reversed the tumor formation effects and inhibited tumor metastasis in vivo152. Moreover, the upregulation of GD2 constitutively activated cMET, a proto-oncogene, resulting in proliferation enhancement, tumor growth, and tumor metastasis153, 154. These data together suggest GD2 as a candidate for the anticancer target. Dinutuximab targeting GD2 displayed a potent ability of breast cancer suppression in both in vivo and in vitro studies155. It inhibited adhesion of breast cancer cells, migration of breast cancer stem cells, and formation of mammospheres through blocking the mTOR pathway155, 156. Except for monoclonal antibodies, CAR-T cells targeting GD2 also demonstrated significant antitumor effects in breast cancers157. The GD2-CAR-T cells recognized the GD2+ breast cancer cells and lysed them in vitro, while T cells successfully expanded and trafficked to tumor sites or metastatic tissues to arrest tumor growth and metastasis in MDA-MB-231 derived orthotopic xenograft mouse models157. To move GD2-CAR-T cell therapy from basic research to clinical application, clinical trials that test the safety and efficacy of GD2-CAR-T cells are underway.

Natural killer group 2, member D (NKG2D) Ligand

Natural killer (NK) cells are lymphocytes in the innate immune system, eliminating the target cells and secreting cytokines to establish an adaptive immune response158. Natural killer group 2, member D (NKG2D), is a transmembrane glycoprotein on the surface of NK cells and functions as an activating receptor159. NKG2D regulates cytotoxicity, cytokine production, and survival160, 161. NKG2D ligands are highly expressed in the tumor microenvironment with cancer cells, infected cells, and autoimmunity cells158. In breast cancer patient samples, evaluation of NKG2D ligand expression showed that it was only expressed on the tumor cells162. Undoubtedly, the NKG2D ligand could be a target for cancer immunotherapy. An in vitro study using miRNA silencing NKG2D ligand showed that decreased NKG2D ligand improved the NK cell-mediated cytotoxicity and avoided immune escape of breast cancer cells38. Moreover, the second-generation of NGK2D-CAR-T cells with the costimulatory domain of 4-1BB/CD27 demonstrated longer T cell persistence in vivo and stronger antitumor effects in TNBC cell cultures and mouse models163. Tumor models with NKG2D-CAR-T cell therapy illustrated promising results in terms of tumor elimination and tumor-free survival164, 165. Collectively, NKG2D is a unique antitumor target with improved clinical outcomes in breast cancer.

Carcinoembryonic antigen (CEA)

Serum tumor markers are a group of proteins that plays an essential role in the early detection of tumor recurrence, metastasis, and screening of many malignancies166. Carcinoembryonic antigen (CEA) is one of the most commonly used serum tumor markers in metastatic breast cancer, which normally implies poor overall survival (OS), disease-free survival (DFS), and a higher tumor burden such as lymph node metastasis, advanced TNM stage, and larger tumor size39, 167. Increased expression of CEA depicts an antitumor probability of CEA-targeting strategies. However, CEA-targeting treatments for breast cancer were less investigated both in preclinical research and clinical studies.

Other targets

The antigen selection is one of the determining factors of CAR-T cell therapy. In addition to the targets discussed above, other targets have also been explored as potential antigens for CAR-T cell therapy. A in silico analysis compared gene expression patterns to identify potential targets for breast cancer immunotherapy, resulting in 36 potentially tumor-surface antigens being discovered, including integrin beta-6 (ITGB6), fibroblast growth factor receptor-4 (FGFR4), and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)168. Only a few studies focused on those potential targets to clarify their therapeutic effects; therefore, more investigation is needed to estimate their potentiality.

CAR-T cell therapy clinical trials in breast cancer

Nineteen antigens targeted by CAR-T cells in breast cancer have been well-studied in preclinical studies, resulting in 12 specific antigens progressing into clinical studies for safety and efficacy tests. 22 CAR-constructed T cells targeting 12 antigens have been investigated in recent years (Table 2). We will discuss in detail in the following sections in terms of target type.

Table 2

The ongoing clinical trials of CAR-T cell therapy in breast cancer.

ClinicalTrials.number	Status	Estimated enrollement	Targeting antigen	Phase	Indicator	Sponsor
NCT04650451	Recruiting	220	HER2	Phase 1	HER2-positive Breast Cancer	Bellicum Pharmaceuticals
NCT03740256	Recruiting	45	HER2	Phase 1	Breast cancer	Baylor College of Medicine
NCT03696030	Recruiting	39	HER2	Phase 1	Breast Cancer/HER2-positive Breast Cancer	City of Hope Medical Center
NCT04430595	Recruiting	100	Her2-, GD2- and CD44v6	Phase 1,2	Breast Cancer	Shenzhen Geno-Immune Medical Institute
NCT01837602	Completed	6	cMET	Phase 1	Metastatic Breast CancerMetastatic Breast Cancer/Triple Negative Breast Cancer	University of Pennsylvania
NCT03060356	Terminated	77	cMET	Early Phase 1	Breast Cancer	University of Pennsylvania
NCT02706392	Recruiting	60	ROR1	Phase 1	Metastatic Triple-Negative Breast Carcinoma/Stage IV Breast Cancer AJCC v6 and v7	Fred Hutchinson Cancer Research Center
NCT02580747	Unknown	20	Mesothelin	Phase 1	Triple Negative Breast Cancer	Chinese PLA General Hospital
NCT02792114	Recruiting	36	Mesothelin	Phase 1	Breast Cancer/Metastatic HER2-negative Breast	Memorial Sloan Kettering Cancer Center
NCT02414269	Recruiting	179	Mesothelin	Phase 1,2	Breast cancer	Memorial Sloan Kettering Cancer Center
NCT02587689	Unknown	20	MUC1	Phase 1,2	Triple-Negative Invasive Breast Carcinoma	PersonGenBioTherapeutics (Suzhou) Co., Ltd.
NCT04020575	Recruiting	69	MUC1*	Phase 1	Metastatic Breast Cancer	Minerva Biotechnologies Corporation
NCT04025216	Recruiting	112	TnMUC1	Phase 1	Triple Negative Breast Cancer	Tmunity Therapeutics
NCT04427449	Recruiting	100	CD44v6	Phase 1,2	Cancers Which Are CD44v6 Positive	Shenzhen Geno-Immune Medical Institute
NCT02915445	Recruiting	30	EpCAM	Phase 1	Breast Cancer Recurrent	Sichuan University
NCT02541370	Completed	20	CD133	Phase 1,2	Breast cancer	Chinese PLA General Hospital
NCT02830724	Suspension	2	CD70	Phase 1,2	Breast cancer	National Cancer Institute (NCI)
NCT02349724	Unknown	75	CEA	Phase 1	Breast cancer	Southwest Hospital, China
NCT04348643	Recruiting	40	CEA	Phase 1,2	Breast cancer	Chongqing Precision Biotech Co., Ltd
NCT03682744	Active, not recruiting	18	CEA	Phase 1	Breast cancer	Sorrento Therapeutics, Inc.
NCT04107142	Not yet recruiting	10	NKG2D	Phase 1	Triple Negative Breast Cancer	CytoMed Therapeutics Pte Ltd
NCT03635632	Recruiting	94	GD2	Phase 1	Phyllodes Breast Tumor	Baylor College of Medicine

3 of 5 RTK targets have progressed into clinical studies. HER2 is the most frequently used RTK for CAR-T cell therapy in breast cancer as currently there are 3 HER2-CAR-T cell therapy and 1 multi-targets CAR-T cell therapies under clinical trials (NCT04650451, NCT03740256, NCT03696030, and NCT04430595). In 2020, Shanghai PerHum Therapeutics conducted an open-label, single-arm, and dose-escalation phase I clinical study to evaluate the safety, tolerability, and major therapeutic outcomes of CAR-modified autologous T cells in HER2 positive solid tumors including breast cancer (NCT04511871). Besides, there are 2 cMET-CAR-T cell therapy clinical trials granted by the University of Pennsylvania. One was terminated according to funding issues (NCT03060356), while the other one has been completed (NCT01837602) with satisfying clinical results. The results showed that breast cancer patients were well-tolerated to intratumorally injection of cMET-CAR-T cells and none of the patients developed drug-related adverse effects greater than grade 1. In addition, cMET-CAR-T cells elicited antitumor effects by triggering the release of the inflammatory cytokines within the tumor70. Furthermore, a phase I clinical trial of ROR1-CAR-T cell therapy was initiated to study the side effects and optimal dose in ROR1-positive cancers including stage IV breast cancers and metastatic TNBC (NCT02706392).

Although 12 cell surface proteins have been well-studied in preclinical research, only 6 of them progressed into further clinical studies. 3 CAR-T cell therapy clinical trials for mesothelin are currently under investigations in phase-I to test the safety issues (NCT02580747, NCT02792114). In contrast, the rest CARs are undergoing phases-I and II clinical trials to test the safety and efficacy (NCT02414269). Besides, 3 CAR-T cell therapy targeting MUC1 were differently constructed in terms of targets, namely the extra domain of the cleaved form of MUC1 (NCT04020575), the aberrantly glycated MUC1 (NCT04025216), and the whole MUC1 (NCT02587689). Moreover, Shenzhen Geno-Immune Medical Institute starts to recruit individuals for a multicenter phase I/II clinical trial to test the safety and efficacy of CD44v6-specific CAR-engineered T cells in CD44v6 positive cancers (NCT04427449). The 3rd generation of EpCAM-CAR-T cells is ongoing a phase I clinical trial for safety and efficacy determination (NCT02915445). Additionally, a phase I/II clinical trial of CD133-CAR-T cell therapy for investigating safety and T cell duration in patients with relapsed and/or chemotherapy-refractory advanced malignancies was completed recently (NCT02541370) but the results were unrevealed. Apart from that, there was a phase I/II clinical trial of CD70-CAR-T cell therapy for breast cancer patients suspended without reason reported (NCT02830724).

Unlike RKT and cell surface proteins, only a few other targets have entered the stage of clinical trials. 2 CEA-specific CAR-T cell therapies are in phase I clinical trials (NCT02349724, NCT03682744) and 1 in phase I and II clinical trials (NCT04348643). Besides, 2 phase I clinical trials of CAR-T cell therapy targeting NKG2D (NCT04107142) and GD2 (NCT03635632) are ongoing to investigate the safety, efficacy, and tolerability of those treatment strategies.

To sum up, although various CAR-T cell therapy clinical trials have been conducted in recent years, only a few results of those clinical trials are public. To better understand the safety and efficacy of CAR-T cell therapy in breast cancers, the results of those ongoing clinical trials are important, and more clinical trials of CAR-T cells targeting different antigens are warranted.

CAR-T cell therapy challenges and strategies to overcome these challenges

Although CAR-T cell therapies showed some promising results in preclinical studies and in clinical trials for treating breast cancers, challenges remain to restrict the clinical applications and limit therapeutic outcomes. In general, these challenges include insufficient recruiting infiltration of CAR-T cells into tumors, immunosuppressive microenvironment in breast tumors, tumor heterogenicity, and the on-target/off-tumor side effects for CAR-T cells11, 169 (Figure 4). For each of these major challenges, various strategies have been proposed to further improve the efficacy of CAR-T cell therapy, which are summarized in Table 3.

Figure 4

The main challenges of CAR-T cell therapy. (A) The tumor microenvironment is lower in oxygen, PH and nutrients, which limits CAR-T cell proliferation and survival. The surrounding fibroblast and ECM inhibit CAR-T cell trafficking and infiltration to tumor sites. The cytokines and checkpoint inhibitors create an immunosuppressive environment around the tumor, which suppresses the function of CAR-T cells. (B) Heterogenicity means different antigen expressions on the surface of tumor cells in terms of type and level, which results in differences in cell response such as cytotoxic or immune escape. (C) The toxicities of CAR-T cell therapy mainly depend on the target. Targeting normal cells results in normal tissue damage or neurotoxicity and genotoxicity. However, life-threatening effects might be evoked when a large amount of tumor cells lysis at the same time and release cytokines and intracellular substances together.

Table 3

CAR-T cell therapy Challenges and strategies in breast cancer.

Challenge	Strategies
Trafficking and infiltration	Designing better matched chemokine receptors on CAR-T cell.
	Using oncolytic viruses to drive CAR-T cells traffic to tumor sites.
	Local administration.
	Constructing CARs to degrades extracellular matrix of tumor cells.
	Targeting the fibroblast activation protein.
Tumor immunosuppressive microenvironment	Constructing T cells with TGFβ receptor.
	Introducing cytokines (such as IL-2, IL-15, IL-12) neutralize immunosuppressive factors.
	Combing with checkpoint inhibitors.
Tumor antigen heterogeneity	Developing multitarget CAR-T cells.
Toxicities	Developing multitarget CAR-T cells.
	Developing affinity-tuned CAR-T cells.
	Developing inhibitory CAR-T cells.
	Introducing suicide genes to CAR-T cells.
	Using transient RNA expression of CARs.

Trafficking and infiltration

CAR-T cells must successfully infiltrate into solid tumors such as breast cancer to specifically target tumor cells, which largely depends on the specific binding between chemokine receptors on the surface of CAR-T cells and the chemokines presenting on tumor cells or tumor microenvironment. The chemokines secreted by cancer cells are varied among tumors; hence it is crucial to identify unique chemokine(s) to guide T cells to recognize a given tumor170. Unfortunately, the mismatches between chemokine receptors on T cells and chemokines on tumor cells were frequently reported171. Two approaches were employed to tackle this problem, which was to design better-matched chemokine receptors on CAR-T cells172 and to use oncolytic viruses with chemotactic chemokine to drive CAR-T cells infiltration into tumors173. However, it remains challenging to pinpoint the corresponding receptors for chemokines and the loaded viruses might trigger immunogenicity.

In addition, local administration increases the number of CAR-T cells in tumor sites and is suitable for various cancers169, 170. The limitations associated with this approach are technique challenged than simple intravenous infusion and uneasy to apply on patients with tumors inaccessible by local delivery11, 170. Moreover, constructing CARs with enzymes to degrade the extracellular matrix of tumor cells or targeting the fibroblast activation protein also aids CAR-T cells infiltration, but the sophisticated modifications might impair T cells' activity174, 175.

Tumor immunosuppressive microenvironment

The inhibitory tumor cytokines especially transforming growth factor β (TGFβ) and immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) accumulate together in tumor sites contributing to the immunosuppression of the tumor microenvironment11. Overcoming these factors is important for the long-term persistence of T cells and the exhibition of antitumor effects. Inhibiting cytokines by directly constructing T cells with TGFβ receptor or indirectly introducing cytokines (such as IL-2, IL-15, IL-12) to neutralize the immunosuppressive factors improved the T cell persistence and efficacy within tumors. However, T cells eliminated by the host immune system and lack of response towards inhibitory cytokines remain as limitations176, 177. Furthermore, the combination therapy of CAR-T cells and checkpoint inhibitors particularly anti-PD1 and anti-PD-L1 blockade also demonstrated better therapeutic outcomes than monotherapy, while adding checkpoint inhibitors might increase the probability of immunogenicity178.

Tumor heterogeneity

Tumor heterogeneity means antigen expression variability on the tumor cell surface in terms of type and level, contributing to another layer of challenge for CAR-T cell therapy. Nevertheless, the successful development of multitarget CAR-T cells has partially tackled this obstacle, showing improved antitumor activities in preclinical studies. One of them has moved forward into clinical trials in breast cancer treatment (NCT04430595). In breast cancer, bispecific CAR-T cells targeting HER2 and MUC1 were successfully constructed and exhibited cytotoxic activities169. Besides, biCAR, triCAR-T cells also demonstrated antitumor effects179, 180. The multitarget approach remarkably recruited CAR-T cells in tumor sites and increased the probability of eliminating subpopulation of tumor cells; moreover, it also decreased the risk of on-target/off-tumor side effects to improve safety181. However, it is still challenging to select the multi-targets on the same tumor cells and develop the corresponding CAR-T cells.

CAR-T cell therapy toxicities

Toxicity is one of the major challenges limiting the application of CAR-T cell therapy. The common toxicities are classified into six types, namely on-target on-tumor toxicity, on-target/off-tumor toxicity, off-target toxicity, neurotoxicity, genotoxicity, and immunogenicity182. To overcome toxicity issues, plenty of approaches have been developed recently, including multitarget CARs, affinity-tuned CARs, inhibitory CAR (iCARs), introducing suicide genes to CAR-T cells, and using transient RNA expressing CARs183. Similar to tumor antigen heterogenicity, CAR-Targeting multi-antigens at once improves safety. Affinity-tuned CARs can distinguish tumor cells and normal cells in terms of antigen expression levels184. iCARs are designed to inhibit cytotoxic effects when CAR-T cells target normal cells185. However, the effects of these two approaches mainly depend on the expression level of the selected targets. And the inhibitory activity of iCARs might interrupt the antitumor effects of T cells. In addition, incorporating suicide genes such as herpes simplex thymidine kinase (HSV-TK), inducible caspase 9 (iCasp9), and CD20 functioning as safety switches control the cytotoxicity of CAR-T cells and decrease the on-target/off-tumor toxicity186, 187. Notwithstanding, suicide genes are correlated with some weaknesses, for example, the unintended elimination of the modified functional CAR-T cells, immunogenicity, and long time to affect188. Another approach that helps reduce toxicity is to use transient RNA expression of CARs, but it shows insufficient tumor infiltration170.

Conclusion and future perspectives

Breast cancer is currently the most commonly diagnosed cancer around the world, ranking first in both incidence and mortality in women1. Resistance development towards the current treatments urges to develop new therapeutics. CAR-T cell therapy is a type of immunotherapies that uses patients' immune cells to fight against cancer10. The successful application of CAR-T cell therapy in hematologic malignancies stimulates its expansion in treating solid tumors, including breast cancer. Within breast cancer cells, altered expressions of several molecules are regarded as the potential targets for CAR-T cell therapy.

The present review discusses the development of CAR-T cell therapy from basic research to clinical trials in breast cancer. We reviewed 19 antigens targeted by CAR-T cells in breast cancer, namely HER2, EGFR, HGFR/cMET, ROR1, AXL, MUC1, MSLN, CD70, CD133, CD44v6, EpCAM, CSGP4, ICAM1, TEM8, TROP2, FRα, GD2, NKG2D, CEA, most of which belong to RTK family and cell surface proteins (Table 1). All 19 antigens have been well studied and showed antitumor effects with tumor growth inhibition and proinflammatory cytokines releasing in preclinical studies, whereas only 12 antigens have progressed into clinical trials (Table 2). Although CAR-T cell therapy has made progress in the last few years, it remained several challenges, such as insufficient trafficking and infiltration, the immunosuppressive environment, lack of tumor-specific or tumor-associated antigens, and CAR-T cell toxicities31, 33. To overcome these challenges and improve CAR-T cell activities, several approaches have been developed for each obstacle (Table 3).

CAR-T cell therapy in breast cancer gains a big achievement till now; however, due to a lack of supporting evidence, it is still a long way from being applied to breast cancer patients. Therefore, to throw CAR-T cell therapy into clinical as early as possible, more clinical trials are needed, and more in-depth investigations are required to improve the safety issues and overcome the challenges of CAR-T cell therapy.